ArticleiScience2026
Dual-input spatio-temporal transformer model: Predicting the efficacy of NACT in breast cancer based on DCE-MRI images.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence in Triple-Negative Breast Cancer: Applications in Diagnosis, Treatment Response, and Prognosis.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a leading malignancy among women worldwide. Neoadjuvant chemotherapy (NACT) can shrink tumors and increase the possibility of breast-conserving surgery, yet many patients respond poorly, causing treatment delays and unnecessary toxicity. Accurate early prediction of NACT response is critical for tailoring therapy. To address this challenge, we developed a dual-input spatiotemporal transformer (DIST) model that analyzes dynamic contrast-enhanced MRI scans obtained before and after the first chemotherapy cycle. By jointly learning spatial and temporal tumor changes, DIST provides early, interpretable imaging-based predictions of treatment response. In validation, the model achieved high accuracy and strong generalizability across institutional and external datasets. These findings demonstrate that DIST enables reliable early assessment of chemotherapy efficacy, offering clinicians a valuable tool to optimize treatment strategies, minimize ineffective therapy, and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.